Buffett InvestorsNZX
Back
AFT.NZ

AFT Pharmaceuticals' Revenue Just Surged 33% - But Is the $3.50 Share Price a Bargain or a Trap?

A Small-Cap Pharma Stock With Big Ambitions

AFT Pharmaceuticals (NZX: AFT) is not your typical sleepy small-cap drug company. The Auckland-based firm just reported a 33% jump in half-year revenue to a record $114.9 million for the six months ending September 2025 - its tenth consecutive period of first-half growth since listing on the NZX. Yet the share price sits at $3.50, roughly midway between its 52-week low of $2.51 and high of $3.80. So why isn't the market more excited, and should investors be paying closer attention?

Recent Performance: The Numbers Tell a Story

AFT's first-half FY2026 results paint a picture of a company accelerating into a new growth phase:

  • •Revenue: $114.9 million (up 33% from $86.7 million in 1H 2025)
  • •EBIT: $4.7 million (swung from a loss in the prior corresponding period)
  • •Net profit after tax: $2.7 million (reversed from a $2.5 million loss)
  • •EBITDA: $6.6 million (up from a $0.7 million loss)
  • •Net debt: $20.9 million (management says this is within target range)

The growth was led by Australia and helped by a full recovery from one-off disruptions in Asian and international markets during the first half of FY2025. The company also reaffirmed its full-year FY2026 operating earnings guidance of $20 million to $24 million - a substantial improvement from the prior year.

The full-year FY2025 results were more muted, with revenue rising a modest 6.5% to $208 million and net income falling 23% to $12.0 million, as lower licensing income and ongoing investment weighed on margins.

Key Metrics: What You're Paying For

At $3.50 per share, AFT carries a market capitalisation of roughly $367 million and trades on a trailing price-to-earnings (P/E) ratio of approximately 21.6x.

Key valuation and income metrics:

  • •Market cap: ~$367 million NZD
  • •Trailing P/E: ~21.6x
  • •Forward P/E: ~20.4x
  • •Dividend yield: ~0.5% (final dividend of 1.8 cents per share, up from 1.6cps in FY2024)
  • •52-week range: $2.51 - $3.80
  • •Beta: 0.40 (indicating lower volatility than the broader market)
  • •Analyst consensus target: $4.35 (suggesting around 24% upside from current levels)

AFT is not a dividend stock. You're buying here for growth, and the P/E of around 21x is reasonable for a pharmaceutical company growing revenue at double digits - provided it delivers on its profit guidance.

The Big Picture: What Does AFT Actually Do?

Founded in 1997 and headquartered in Takapuna, Auckland, AFT Pharmaceuticals develops, markets, and distributes pharmaceutical products across New Zealand, Australia, Asia, and international markets. Its portfolio spans over-the-counter, prescription, and hospital channels and includes both proprietary and in-licensed products.

The company's well-known brands include Maxigesic (a patented combination painkiller), Crystaderm (first aid cream), Kiwisoothe, and a wide range of products across allergy, cold and flu, digestive health, eye care, skin care, and hospital use.

What sets AFT apart from many small-cap pharma companies is its dual-track strategy: it operates a profitable, cash-generative business in Australasia while investing strategically in research and development and international expansion. Its R&D spend sits at around $15 million annually, focused on eight projects including a novel intravenous iron formulation, an antibiotic eyedrop, and a topical treatment for strawberry birthmarks. The company also maintains active out-licensing and in-licensing programs that leverage its intellectual property globally.

Strategic partnerships are increasingly important. AFT extended its US licensing agreement with Hikma Pharmaceuticals for Maxigesic and has a collaboration with Belgium's Hyloris Pharmaceuticals on a novel injectable. It is also building online marketplaces and direct-to-consumer channels via Amazon in North America and Australia.

What to Watch: Opportunities and Risks

AFT's bull case is straightforward but not without execution risk.

The bull case:

  • •$300 million revenue target by FY2027: Management has repeatedly reaffirmed this goal, which implies roughly 45% revenue growth over two years. Hitting that number would transform the investment case.
  • •International expansion: The company is deliberately building business hubs in international markets that share characteristics with its successful Australasian operations. Licensing agreements - including its novel IV iron formulation in China - represent high-margin, capital-light growth.
  • •R&D pipeline: Late-stage assets could unlock significant value if clinical trials succeed and regulatory approvals follow.
  • •Improving profitability: The swing to EBIT profit in 1H 2026 suggests operating leverage is starting to kick in.

The risks:

  • •Profitability remains thin: While revenue is growing fast, net profit margins have been volatile. AFT earned just $12 million on $208 million of sales in FY2025 - a margin of only 5.8%. Licensing income, which boosted profits in prior years, can be lumpy and unpredictable.
  • •Capital intensity: R&D, ERP system upgrades, and international hub expansion are eating cash. Net debt of $20.9 million is manageable but not insignificant for a company this size.
  • •Execution risk: A 45% revenue jump to $300 million in two years requires flawless execution across multiple geographies and product launches.
  • •Currency and regulatory exposure: International revenues bring forex risk, and pharmaceutical markets are heavily regulated. Delays or rejections can derail licensing deals.
  • •Low liquidity: Average daily trading volume sits around 13,000 shares. For larger investors, building or exiting a position can move the price.

The Bottom Line

AFT Pharmaceuticals sits at an inflection point. The 33% revenue surge in 1H 2026 and the return to operating profit are genuine positives, and a $300 million revenue run rate by FY2027 would make today's $3.50 share price look cheap in hindsight. The modest beta and strong Australasian franchise provide a measure of stability.

But the stock is still a small-cap growth story with execution risk. The P/E of ~21x is fair only if the company hits its earnings guidance and progresses toward that ambitious revenue target. If you're comfortable with the volatility and the long runway, AFT represents a rare New Zealand pharmaceutical growth play with global ambitions. If you prefer predictable cash flows and fat dividends, you'll want to look elsewhere.

*Disclaimer: This article is for educational and informational purposes only. It does not constitute financial advice. Stock data may not be real-time. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.*